Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267054 | 0.92 | ADORA2A (0.33) | KDM4ESMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL16267043 | 0.82 | KDM4E (0.38) | KDM4ESMN1; SMN2ALDH1A1HTTL3MBTL1 | |
| SCHEMBL14964962 | 0.81 | ADORA2A (0.32) | — | |
| SCHEMBL16294535 | 0.79 | POLB (0.50) | HTTKMT2ALMNAPOLB | |
| SCHEMBL14969429 | 0.79 | SMN1; SMN2 (0.34) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL14964980 | 0.76 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL14964940 | 0.76 | — | — | |
| SCHEMBL14964798 | 0.76 | ALDH1A1 (0.46) | KDM4EALDH1A1HTTKMT2APOLB | |
| SCHEMBL14968856 | 0.72 | CRHBP (0.33) | L3MBTL1 | |
| SCHEMBL14965215 | 0.71 | KMT2A (0.46) | HTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| EP-2780344-A1 | THIENO [2, 3 - C]PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072693-A1 | THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNK3, KCNJ1 | KDM4E 1338/4885SMN1; SMN2 3984/4885ALDH1A1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.